The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 24.25
Bid: 24.00
Ask: 24.50
Change: -1.00 (-3.96%)
Spread: 0.50 (2.083%)
Open: 25.25
High: 25.25
Low: 24.25
Prev. Close: 25.25
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Aptamer says struggling to convert pipeline

Fri, 05th May 2023 11:11

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

----------

AIM - WINNERS

----------

Bushveld Minerals Ltd, up 20% at 4.35 pence, 12-month range 3.5p-10.6p. The South Africa-focused vanadium producer and energy storage solutions company enters into term sheet with Orion Mine Finance to refinance its existing convertible loan note. Will refinance around USD45 million due in November into three components, including a USD27 million three-year term loan, new CLN of USD13.5 million maturing in 2028, and conversion of USD4.5 million of existing CLN into shares at 6p each. "The proposed refinancing will resolve a large liability that became current in 2023 and will remove significant near-term pressure on the company's balance sheet, in the process supporting sustainable growth and cash generation of our business," says Chief Executive Fortune Mojapelo.

----------

Sareum Holdings PLC, up 12% at 140.05p, 12-month range 55.1p-264p. The Cambridge-based biotechnology company developing kinase inhibitors for autoimmune disease and cancer wins approval to conduct phase 1 clinical studies on SDC-1801 in Australia. SDC-1801 is a TYK2/JAK1 inhibitor being investigated as a potential new therapeutic for autoimmune diseases, with a focus on psoriasis. Will work alongside specialist clinical units in Melbourne to begin a phase 1a trial as soon as possible.

----------

AIM - LOSERS

----------

Aptamer Group PLC, down 46% at 13.78p, 12-month range 13p-122.95p. The developer of novel Optimer binders for the life sciences industry updates on the financial year ending June 30. In the first 10 months, revenue was around GBP1.4 million, with its pipeline taking "longer than expected to convert". The delays were especially apparent in licensing and royalty-based contracts. It now expects annual revenue to be "materially" below the previous year's level of GBP4.0 million. It reports a "healthy" pipeline across fee-for-service and licensing, with some of the revenue to fall in the current year, but most - "if converted" - in the next year. With cash running low at GBP700,000 at the end of April, the firm is mulling a range of funding options, which could be non-dilutive or dilutive in nature.

----------

By Elizabeth Winter, Alliance News senior markets reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
19 Apr 2024 12:16

IN BRIEF: Sareum falls as issues shares to RiverFort Global

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company - Issues 3.0 million new shares in the company to RiverFort Global Opportunities PCC Ltd. Issue is in line with facility announced in August. Says facility has an outstanding balance of GBP220,000.

Read more
4 Apr 2024 17:24

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
2 Apr 2024 17:35

TRADING UPDATES: Sareum ups retail offer; SThree nabs former ITV exec

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
28 Mar 2024 13:44

EARNINGS AND TRADING: Northamber loss widens; Ethernity contract boost

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
15 Mar 2024 13:11

Sareum allowed European patent for primary kinase inhibitor asset

(Sharecast News) - Biotechnology company Sareum announced on Friday that the European Patent Office had issued a notice of allowance for a patent concerning SDC‐1801, its primary TYK2/JAK1 kinase inhibitor currently undergoing clinical trials in Australia.

Read more
15 Mar 2024 12:46

Sareum Holdings touts new patent allowance for autoimmune therapy

(Alliance News) - Sareum Holdings PLC on Friday celebrated a new patent allowance for SDC-1801, which is a therapy designed to treat a range of autoimmune diseases.

Read more
12 Mar 2024 15:23

Sareum shares slump on widened loss and funding talks

(Alliance News) - Sareum Holdings PLC share fell on Tuesday, after it said it expects to report a widened interim loss.

Read more
15 Feb 2024 13:22

Sareum reports positive progress in psoriasis programme

(Sharecast News) - Sareum announced significant milestones in its phase 1a clinical trial for SDC-1801, its lead programme aimed at addressing autoimmune diseases such as psoriasis, on Thursday.

Read more
15 Feb 2024 11:20

Sareum hails safety profile for SDC-1801 after phase 1 trial

(Alliance News) - Sareum Holdings PLC on Thursday said SDC-1801 has the potential to achieve therapeutically effective dose levels with no serious adverse events, following a phase 1 trial.

Read more
15 Feb 2024 10:52

AIM WINNERS & LOSERS: DSW warns on earnings amid tepid M&A markets

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
2 Jan 2024 13:54

Sareum shares jump on cancer drug licensing deal

(Sharecast News) - Shares in AIM-listed biotech group Sareum jumped by a fifth on Tuesday after its co-development partner for cancer treatment SRA737 signed a commercialisation licence agreement with a US biopharma company.

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 10:05

AIM WINNERS & LOSERS: LungLife AI soars on test; Plexus falls on deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
2 Jan 2024 09:31

Sareum soars as partner agrees SRA737 licence with US biopharma firm

(Alliance News) - Sareum Holdings PLC shares surged on Tuesday, after it said its co-development partner CRT Pioneer Fund entered into a development and commercialisation licence for SRA737 with an unnamed US biopharmaceutical company.

Read more
14 Dec 2023 20:20

EARNINGS AND TRADING: CleanTech raises GBP520,000 in open offer

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.